Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 4
1(33.3%)
3Total
N/A(2)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07118462Phase 4Recruiting

HighCycle Study: Acetazolamide, High Altitude and Plasma Volume

Role: lead

NCT04251364Not ApplicableCompleted

Treatment of Chronic Mountain Sickness

Role: lead

NCT04604249Unknown

Prevalence of COVID-19 in High Altitude : Insights From the Highest City of the World

Role: lead

NCT02778659Not ApplicableCompleted

Hypnotic Intake and Motor and Cognitive Performances at High Altitude

Role: lead

All 4 trials loaded